$NTLA News

Intellia: Phase 3 HAELO Win Doesn't Fix The Commercial Problem

Wolfe Research Downgrades Intellia Therapeutics to Underperform, Announces $9 Price Target

Intellia Therapeutics: An Overvalued Biotech With Little To No Commercial Potential

Wedbush Maintains Neutral on Intellia Therapeutics, Raises Price Target to $17

Intellia Therapeutics (NTLA) Could Be 37% Undervalued After Phase 3 Lonvo Z Success

NTLA Surges 38% in a Month: Should You Buy, Sell or Hold the Stock?

Intellia Therapeutics (NTLA) Stock Looks Rich On Sales But Weak On Returns

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Is Intellia Therapeutics, Inc. (NTLA) A Good Stock To Buy Now?

Strength Seen in Intellia Therapeutics (NTLA): Can Its 23.2% Jump Turn into More Strength?

Intellia Therapeutics (NTLA) Skyrockets 23% on Encouraging Lonvo-Z Results

Intellia Surges; Can Its Gene-Editing Drug Solve The Chronic Treatment Problem?

Intellia's One-Time Gene Editing Therapy Gains Ground Against Rivals In Rare Swelling Disorder

Citizens Reiterates Market Outperform on Intellia Therapeutics, Maintains $30 Price Target

Wedbush Reiterates Neutral on Intellia Therapeutics, Maintains $12 Price Target

Why Is NTLA Stock Jumping 5% Premarket Today?

HC Wainwright & Co. Reiterates Buy on Intellia Therapeutics, Maintains $25 Price Target

Reported Saturday, Intellia Therapeutics' Lonvo-z Achieves 87% Attack Reduction And 62% Attack-Free Rate In Phase 3 HAELO Trial With Results Published Simultaneously In New England Journal Of Medicine

Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)